BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

BioMarin to buy rare disease drugmaker Inozyme for $270M

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency

BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme

BioMarin, multiple quarters into its portfolio refinement, is inking a small acquisition for a rare disease therapy about two years before a potential regulatory approval. The California drugmaker plans to buy Boston-based Inozyme Pharma and ...